Role of Concomitant @entity2995 Injection in Small-Gauge Vitrectomy for Idiopathic XXXX .

@entity1 @entity2995 @entity6654
PURPOSE: The concomitant use of @entity2995 (TA) at the completion of pars plana vitrectomy for the treatment of epiretinal membrane may speed up the anatomical and functional outcomes of surgery. We report the outcome of @entity1 undergoing small-gauge vitrectomy for @entity6654 with or without adjuvant TA therapy. DESIGN: This is a retrospective, single-center case series. METHODS: We included 75 eyes of 75 individual @entity1 . Twenty-six @entity1 (group A) had an adjuvant TA injection during surgery, whereas 49 @entity1 (group B) were not injected. We assessed the @entity1 for change in visual acuity (VA) and central macular thickness before and after surgery. RESULTS: Group A had a mean logarithm of the minimum angle of resolution VA of 0.63    0.33 and 0.51    0.31 preoperatively and 3 months after surgery, respectively. Group B had a mean logarithm of the minimum angle of resolution VA of 0.47    0.17 and 0.36    0.17 preoperatively and 3 months after surgery, respectively. No significant difference was found between the groups in change of VA. The mean central macular thickness for groups A and B @entity1 before surgery was 474.12    120  m and 445    85  m, decreasing to 369    70  m and 386    60  m at the final visit, respectively. The difference in macular thickness reduction between the groups was statistically significant. CONCLUSIONS: Anatomical and functional improvement was found in both groups after surgery. Macular thickness was further reduced in the group of @entity1 treated with adjuvant TA.
